Compare Johnson & Johnson (JNJ) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Sibanye Stillwater Ltd — how do they compare? Johnson & Johnson trades at $250.33 (market cap $598.96B), while Sibanye Stillwater Ltd trades at $8.33 (market cap $5.66B). The key difference: Johnson & Johnson is far larger — about 105.8× Sibanye Stillwater Ltd's market cap, and Sibanye Stillwater Ltd pays the higher dividend (3.89%). Which is the better fit depends on your goals.
| JNJ | SBSW | |
|---|---|---|
Market Cap | $598.96B | $5.66B |
Volume | 6,156,228 | — |
Sector | Health | Basic Materials |
52-Week High | $267.24 | $21.12 |
52-Week Low | $164.36 | $7.27 |
Enterprise Value | $631.90B | $7.28B |
Dividend Yield | 2.15% | 3.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Sibanye Stillwater (SBSW) trades at $8.02, up 0.25% on the day, with technical indicators showing a bearish trend. The company reported a net loss of $7.30 billion in 2024, though revenue remained stable at $112.13 billion. Recent news highlights management's focus on debt reduction and operational improvements, with Seeking Alpha noting a 5x YoY EBITDA surge driven by strong PGM and gold prices as of July 3, 2026.
The stock presents a high-risk opportunity with a consensus price target of $14.25, implying significant upside, but faces headwinds from negative profitability metrics and volatile commodity prices. Investors should weigh the potential turnaround against ongoing operational challenges and macroeconomic risks in the mining sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
